According to CNBC, on September 20, 2021, Pfizer and BioNTech reports that a smaller dose of its COVID-19 vaccine is safe and generates a “robust” immune response in a clinical trial of kids ages five to 11.

According to the American Academy of Pediatrics, as students get back to school with the delta variant surging across the country, children’s COVID-19 cases are disturbingly high, with 243,000 new infections during the week ending Sept. 9th, which is the second-highest number of such cases since the beginning of the pandemic.

The data, which included more than 2,200 children, will be submitted to the Food and Drug Administration (FDA) and other health regulators by the end of September. Thus, if the FDA review takes as long as it did for 12- to 15-year-olds, the vaccines could be available by the end of October.

For more from CNBC, click here.